PDUFA Action Date for the Arimoclomol NDA is September 21, 2024 CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably (11 yes, 5 no) …
Tag
Showing: 4 - 6 of 41 RESULTS
NPC
FDA Rare Disease Innovation Hub to Enhance and Advance Outcomes for Patients
FDA Press Release Link: FDA Rare Disease Innovation Hub to Enhance and Advance Outcomes for Patients | FDA By: Patrizia Cavazzoni, MD, Director, Center for Drug Evaluation and Research and Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research An estimated 10,000+ rare diseases affect more than 30 million people – approximately one …
Zevra Announces FDA Advisory Committee Meeting To Review Arimoclomol For The Treatment Of NPC
July 9, 2024 at 9:00 AM EDT Meeting with the recently formed GeMDAC set for August 2, 2024 CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has indicated that it will convene a meeting with the recently formed Genetic …